Sandra and Edward Meyer Cancer Center

For the first time, Weill Cornell Medicine researchers have demonstrated that Hodgkin lymphoma cancer cells from patient samples are immune cells stuck in an “identity crisis.” 

A team of Weill Cornell Medicine investigators is working to cross-train the next generation of cancer researchers in cancer biology and the use of artificial intelligence tools for research.

Temporarily disabling a protein complex that organizes DNA into loops inside the cell’s nucleus drastically disrupted the three-dimensional structure of the genome, but surprisingly most genes continued to function as usual, Weill Cornell Medicine researchers found. 

We sat down with Dr. Jia Ruan to learn more about her clinical research and how she thinks it will help lymphoma patients.

A $1 million Research Scholar Grant from the American Cancer Society will help a multi-institution team led by Dr. Bishoy Faltas, associate professor of medicine at Weill Cornell Medicine, to develop new therapy combinations for hard-to-treat urinary tract cancers.

Six researchers from Weill Cornell Medicine have received Young Investigator Awards from the Prostate Cancer Foundation. 

An enigmatic type of circulating tumor cell called a dual-positive cell is associated with shorter survival time in patients with advanced breast cancer, according to a study led by investigators at Weill Cornell Medicine. 

A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel Deaconess Medical Center. 

Dr. Ekta Khurana, an associate professor of systems and computational biomedicine at Weill Cornell Medicine, has received a two-year, $1 million Challenge Award from the Prostate Cancer Foundation to work with researchers from Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center on an AI-based method for early detection of treatment-resistant prostate tumor subtypes.

Awards, honors and achievements for the month of February. 

When food is scarce, stress hormones direct the immune system to operate in “low power” mode to preserve immune function while conserving energy, according to researchers at Weill Cornell Medicine.

Dr. George Coukos, an internationally renowned expert on cancer immunology, is launching the Ludwig Laboratory for Cell Therapy at Weill Cornell Medicine.

A new study reveals how bacteria in the gut can help determine whether the amino acid asparagine from the diet will feed tumor growth or activate immune cells against the cancer​, according to researchers at Weill Cornell Medicine.

A new single-cell profiling technique has mapped pre-malignant gene mutations and their effects in solid tissues for the first time, in a study led by investigators at Weill Cornell Medicine and the New York Genome Center.

A whole-genome sequencing approach shows early promise over current commercial methods for identifying more patients likely to benefit from PARP inhibitor cancer treatments, according to a study led by Weill Cornell Medicine and NewYork-Presbyterian investigators.

A class of ultrasmall fluorescent core-shell silica nanoparticles developed at Cornell is showing an unexpected ability to rally the immune system against melanoma and dramatically improve the effectiveness of cancer immunotherapy.

Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During their preparation for this battle, B cells transiently revert to a more flexible, or plastic, stem-cell-like state in the lymph nodes, according to a new preclinical study from Weill Cornell Medicine investigators. 

Dr. John Blenis's lab discovered that low levels of folate, a B vitamin essential for cell growth, can trigger specific genetic changes found in lung tumors, establishing a link between nutrition and cancer, which may open new dietary approaches for prevention and treatment.

Dr. Despina Siolas, assistant professor of medicine at Weill Cornell Medicine, is working to personalize treatment for pancreatic cancer and develop new therapeutic regimens that save more patient lives.

Chemotherapy activates a stress sensor in immune cells, triggering inflammation and nerve damage, which may help explain why many cancer patients experience debilitating pain as a side effect, according to a new study by Weill Cornell Medicine and Wake Forest University School of Medicine researchers.